127 related articles for article (PubMed ID: 35328239)
1. Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience.
Parente P; Maiorano BA; Ciardiello D; Cocomazzi F; Carparelli S; Guerra M; Ingravallo G; Cazzato G; Carosi I; Maiello E; Bossa F
Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328239
[No Abstract] [Full Text] [Related]
2. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors.
Tang T; Abu-Sbeih H; Luo W; Lum P; Qiao W; Bresalier RS; Richards DM; Wang Y
Scand J Gastroenterol; 2019 May; 54(5):538-545. PubMed ID: 31079556
[No Abstract] [Full Text] [Related]
3. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies.
Zhang ML; Neyaz A; Patil D; Chen J; Dougan M; Deshpande V
Histopathology; 2020 Jan; 76(2):233-243. PubMed ID: 31361907
[TBL] [Abstract][Full Text] [Related]
4. Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors.
de Malet A; Antoni G; Collins M; Soularue E; Marthey L; Vaysse T; Coutzac C; Chaput N; Mateus C; Robert C; Carbonnel F
Eur J Cancer; 2019 Jan; 106():106-114. PubMed ID: 30476730
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
6. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Enteric Infections in Patients on Immune Checkpoint Inhibitors and Impact on Management and Outcomes.
Magahis PT; Satish D; Esther Babady N; Kamboj M; Postow MA; Laszkowska M; Faleck DM
Oncologist; 2024 Jan; 29(1):36-46. PubMed ID: 37721546
[TBL] [Abstract][Full Text] [Related]
8. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
9. Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review.
Collins M; Soularue E; Marthey L; Carbonnel F
Clin Gastroenterol Hepatol; 2020 May; 18(6):1393-1403.e1. PubMed ID: 32007539
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor-related gastrointestinal toxicity in patients with malignancy involving the luminal gastrointestinal tract and its impact on cancer outcomes.
Yu K; Mathew A; Abraham F; Amin R; Kono M; Overman M; Zhao D; Khan A; Khan MA; Thomas AS; Wang Y
Ann Gastroenterol; 2022; 35(5):514-521. PubMed ID: 36061157
[TBL] [Abstract][Full Text] [Related]
11. Atezolizumab, a PD-L1 Inhibitor: An Association of Bleeding Gastric Ulcer With Its Use.
Bapatla A; Tariq T; Haider MB; Mohamad B
Cureus; 2021 Jun; 13(6):e15637. PubMed ID: 34150414
[TBL] [Abstract][Full Text] [Related]
12. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
Chai QQ; Du JY; Zhu J; Wu B
Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
[No Abstract] [Full Text] [Related]
13. Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis.
Grover S; Ruan AB; Srivoleti P; Giobbie-Hurder A; Braschi-Amirfarzan M; Srivastava A; Buchbinder EI; Ott PA; Kehl KL; Awad MM; Hodi FS; Rahma OE
JCO Oncol Pract; 2020 Sep; 16(9):e933-e942. PubMed ID: 32401685
[TBL] [Abstract][Full Text] [Related]
14. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management.
Shivaji UN; Jeffery L; Gui X; Smith SCL; Ahmad OF; Akbar A; Ghosh S; Iacucci M
Therap Adv Gastroenterol; 2019; 12():1756284819884196. PubMed ID: 31723355
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects.
Liu C; Amin R; Shatila M; Short N; Altan M; Shah A; Alhalabi O; Okhuysen P; Thomas AS; Wang Y
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3965-3976. PubMed ID: 36030431
[TBL] [Abstract][Full Text] [Related]
17. Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis.
Yang W; Men P; Xue H; Jiang M; Luo Q
Front Oncol; 2020; 10():197. PubMed ID: 32211312
[No Abstract] [Full Text] [Related]
18. Checkpoint Inhibitor-Induced Colitis: An Update.
Losurdo G; Angelillo D; Favia N; Sergi MC; Di Leo A; Triggiano G; Tucci M
Biomedicines; 2023 May; 11(5):. PubMed ID: 37239166
[TBL] [Abstract][Full Text] [Related]
19. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.
Abu-Sbeih H; Tran CN; Ge PS; Bhutani MS; Alasadi M; Naing A; Jazaeri AA; Wang Y
J Immunother Cancer; 2019 May; 7(1):118. PubMed ID: 31053161
[TBL] [Abstract][Full Text] [Related]
20. Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis.
Saji A; Chopra M; Jacob J; Altan M; Alhalabi O; Shah AY; Qiao W; Wang Y; Thomas A
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5841-5852. PubMed ID: 36585982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
